In postmenopausal women with osteoporosis, is strontium ranelate more effective than placebo for reducing the risk of vertebral fractures?

**MAIN RESULTS**

Fewer patients who received strontium ranelate had new vertebral fractures and vertebral height loss of >1 cm than patients who received placebo (table). Patients in the treatment group also had increased BMD at the lumbar spine, femoral neck, and total hip (mean percent change from baseline 14.4%, 8.3%, and 9.8%, respectively; p<0.001). The groups did not differ for non-vertebral fracture (table) or adverse events.

**CONCLUSION**

In postmenopausal women with osteoporosis, strontium ranelate reduced the risk of vertebral fractures.

---

**Commentary**

Strontium was originally identified in lead mines near Strontian, Scotland in the late 1700s. It was used to treat osteoporosis in the 1950s but was found to cause unacceptable mineralisation defects due to the high doses used at the time. A renewed interest now exists in strontium ranelate, which increases bone formation and decreases bone resorption. 4 major trials have examined strontium ranelate for the treatment of postmenopausal osteoporosis. 2 dose finding trials, PREVOS 1 and SOTI 2 (with a total sample of >500 women), showed that strontium ranelate increased corrected lumbar spine BMD in a dose dependent manner over 2 years (BMD must be corrected because strontium causes a false elevation in BMD as measured by DEXA). The current 3 year trial by Meunier et al showed that 2 g daily of oral strontium ranelate reduced morphometric vertebral fractures by 47% (number needed to treat [NNT] = 17) at 1 year and by 36% (NNT = 9) by 3 years. These results indicate efficacy that is comparable to but not remarkably better than currently available osteoporosis agents. A large ongoing trial is examining the efficacy of strontium ranelate in preventing hip fractures in postmenopausal women with osteoporosis, and preliminary results are promising.

Potential side effects of strontium ranelate include diarrhoea and asymptomatic transient increase in creatine kinase. However, before strontium can become an attractive treatment option for osteoporosis, studies of its long term safety, effectiveness, and cost effectiveness relative to other agents are needed.
Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women with osteoporosis

*Evid Based Med* 2004 9: 149
doi: 10.1136/ebm.9.5.149

Updated information and services can be found at:
http://ebm.bmj.com/content/9/5/149

These include:

**References**
This article cites 4 articles, 0 of which you can access for free at:
http://ebm.bmj.com/content/9/5/149#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Injury (154)
- Menopause (including HRT) (85)
- Musculoskeletal syndromes (219)
- Osteoporosis (55)
- Geriatric medicine (134)
- Diet (262)
- Clinical diagnostic tests (440)
- Clinical trials (epidemiology) (1596)
- Drugs: CNS (not psychiatric) (262)
- Neurogastroenterology (105)
- Radiology (337)
- Radiology (diagnostics) (251)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/